Race Oncology share price leaps 5% on quarter of ‘major advances’

The Race Oncology Ltd (ASX: RAC) share price is climbing higher on Friday after the drug developer revealed its June quarter activity report.

At the time of writing, shares in the company are trading 5.4% higher to $2.15 after initially having a slow start to the day.

The significant move is in contrast with an underwhelming performance from the S&P/ASX 200 Index (ASX: XJO) today, with the benchmark inching only 0.06% ahead.

Race Oncology share price boosted by progress

Here are some of the main highlights from Race Oncology’s latest quarterly activities report:

  • Completion of Phase 1b involving relapsed Acute Myeloid Leukaemia trial of Zantrene
  • Moving to Phase 2 efficacy study with plans to recruit 17 patients
  • Positive findings for heart protection from chemotherapy treatment
  • On-market share buyback for up to 4 million shares
  • Net cash outflow of $2.14 million during the quarter
  • Cash position of $33.54 million at the end of June

What else happened in the quarter?

The three-month period was a pivotal time of progress for the company’s Zantrene drug. In addition to successfully completing its Phase 1b trial, Race made several other important findings involving the treatment.

For example, on 22 June, Race announced interim results from its preclinical melanoma research program. Based on the data, Zantrene was found to improve cancer immunotherapy in three key ways. These are the direct killing of melanoma cells, activation of immune cells, and reducing immune evasion genes.

Moreover, the company informed shareholders of findings suggesting heart protection from the damaging effects of chemotherapy when using Zantrene. This information was disclosed to the market on 30 June, followed by a 13% jump in the Race Oncology share price the next day.

What did management say?

In light of the reassuring results, Race Oncology management shared a positive sentiment with shareholders today.

Commenting on the quarter, Race CEO Phillip Lynch said:

We were particularly pleased to see the human heart cell data corroborated in a whole mouse model, confirming that Zantrene when used with doxorubicin protects from cardiac damage, while also improving anti-cancer efficacy. We are now developing clinical programs as we pursue realisation of this high-value opportunity for Zantrene.

What’s next?

Looking to the future, investors can expect more information regarding drug development efforts during the half. Specifically, the company will progress with preclinical in vitro for breast cancer, multiple myeloma, and kidney cancer.

Furthermore, preclinical in vivo (in animal) studies will commence for the same diseases. However, results are said to be shared once relevant IP protections are in place.

Lastly, clinical trials are expected to take place in this year’s third quarter.

Race Oncology share price snapshot

While the Race Oncology share price has been on a winning streak in the last month, rising 30%, the year-to-date performance is less impressive.

Since 2022 began, shares in the company have fallen 40% in value. For reference, 15 June 2022 marked a 52-week low, as the Race Oncology share price hit $1.45.

The post Race Oncology share price leaps 5% on quarter of ‘major advances’ appeared first on The Motley Fool Australia.

Should you invest $1,000 in Race Oncology Limited right now?

Before you consider Race Oncology Limited, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Js1lAt7

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s